Bionomics Limited (NASDAQ:BNOX – Get Free Report) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 70,400 shares, an increase of 8.6% from the December 31st total of 64,800 shares. Based on an average trading volume of 230,100 shares, the days-to-cover ratio is presently 0.3 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Bionomics in a research report on Thursday, December 7th.
Hedge Funds Weigh In On Bionomics
Bionomics Stock Performance
NASDAQ BNOX opened at $0.97 on Thursday. Bionomics has a twelve month low of $0.87 and a twelve month high of $7.71. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $1.25 and a 200 day simple moving average of $1.91.
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
- Five stocks we like better than Bionomics
- Stock Sentiment Analysis: How it Works
- 2 REIT stocks set to surge due to red hot data center demand
- Why Invest in 5G? How to Invest in 5G Stocks
- How and when to use LEAPS stock options
- How to Effectively Use the MarketBeat Ratings Screener
- 3 reasons airline stocks are a buy right now
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.